2018
DOI: 10.4103/ijo.ijo_35_18
|View full text |Cite
|
Sign up to set email alerts
|

Intravitreal therapeutic agents in noninfectious uveitic macular edema

Abstract: The management of uveitis is challenging for most treating ophthalmologists. The treatment of uveitis often requires the use of high dose of systemic corticosteroid and immunosuppressive agents, which are almost always associated with potential side effects. Intravitreal medications have become a popular mode of drug administration in uveitis patients as they provide high volume of drug to the target tissues, eliminating the risk of systemic toxicity. There has been tremendous development in the intravitreal t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 13 publications
(3 citation statements)
references
References 73 publications
(110 reference statements)
0
3
0
Order By: Relevance
“…Because the duration of IVTA is short, intravitreal dexamethasone implant is thought by many to produce a more sustained effect than IVTA but was comparable with IVTA at 8 weeks in decreasing the central subfield thickness in uveitic macular edema. 25 27 There are case reports that suggest that the addition of intravitreal dexamethasone implant improved visual outcomes, macular edema, and resolution of RV, in entities, such as BD-associated uveitis and RV, and in IRVAN. 28 , 29 There were some elevations in intraocular pressure noted in some of these reports, following the use of the steroid implant.…”
Section: Immunosuppressantsmentioning
confidence: 99%
“…Because the duration of IVTA is short, intravitreal dexamethasone implant is thought by many to produce a more sustained effect than IVTA but was comparable with IVTA at 8 weeks in decreasing the central subfield thickness in uveitic macular edema. 25 27 There are case reports that suggest that the addition of intravitreal dexamethasone implant improved visual outcomes, macular edema, and resolution of RV, in entities, such as BD-associated uveitis and RV, and in IRVAN. 28 , 29 There were some elevations in intraocular pressure noted in some of these reports, following the use of the steroid implant.…”
Section: Immunosuppressantsmentioning
confidence: 99%
“…Most often they use long-term steroids and cyclosporine therapy, having such side effects as cataracts, osteoporosis, diabetes and hypertension [101,102]. Conventional immunosuppressive therapy and cytotoxic drugs do not prevent recurrent exacerbations and complex treatment with plasmapheresis provides more stable results [69,103]. Plasmapheresis is used in combination with blood cells ozonation [104].…”
Section: Atypical Optic Neuritismentioning
confidence: 99%
“…Conventional techniques use a 20-gauge microvitreoretinal (MVR) blade to create the sclerotomy wound. 2 We demonstrate use of a 2.4-mm keratome blade to create the sclerotomy wound.…”
mentioning
confidence: 99%